Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer – guidance (TA693)

Olaparib plus bevacizumab is recommended, within the Cancer Drugs Fund for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults when certain criteria are met.

SPS commentary:

The criteria are:

    There has been a complete or partial response after first-line platinum-based chemotherapy plus bevacizumab, and
    The cancer is associated with homologous recombination deficiency.

National Institute for Health and Care Excellence